Pharmacokinetic and Half-Life Studies

The “Tg32” expresses human FcRn at physiological levels allowing the generation of predictive PK data.

Tg32 carries the endogenous human promoter and all known regulatory sequences. This model is commonly used to model human PK behavior of therapeutic antibodies, giving the highest half-lives.

Correlation of a human mAb stability between transgenic humanized mice (Tg32) or non-human primates (NHP) and humans. The correlation coefficient is shown in the graph. The axis represent the day at which the same relative concentration of the mAb is seen in humans (vertical axis) or the other species (horizontal axis)

The Tg276 model is optimal for screening similar antibodies for subtle PK differences

B6.Cg-Fcgrt^{tm1Dcr Tg}(CAG-FCGRT)276Dcr/DcrJ - 004919

Early evaluation of antibody PK in vivo allows resource dedication to the most promising candidate. Discrimination between similar Fc variants allows selection of the variant with superior PK. Prediction of human PK performance eases decisions regarding optimum dosing and reduce adverse clinical side-effects

The Tg276 mouse line, expressing human FCGRT ubiquitously, can be effectively used to detect subtle half-life differences in mAb variants. The vertical axis represents the percentage of mAb remaining in circulation, the horizontal axis shows the days after injection.

The Tg32.scid model allows for PK assessment of therapeutics that might otherwise result in immunogenicity

B6.Cg-Fcgrt^tm1Dcr Prkdc^scid Tg(FCGRT)32Dcr/DcrJ - 01844

A small subset of therapeutics may elicit ADA (anti-drug antibody) responses due to the intact immune system in the standard Tg32 mouse model. The scid allele makes these mice immunodeficient, therefore allowing the ability to test potential immunogenic human immunoglobulin and Fc-domain based therapeutics.

Anti-drug antibody (ADA) response in Tg32 mice can obcure the actual half-life of a human antibody. Tg32 harboring a mutation in the Prkdc gene (Tg32 scid) do not produce antibodies and cannot mount an ADA response. On the vertical axis in the concentration of the human IgG in nmoles/I, while on the horizontal axis are the days post-injection.

The Tg32.Albumin model can be used to determine the pharmacokinetics of albumin-based drug

B6.Cg-Tg(FCGRT)32Dcr Alb^em12Mvw Fcgrt^tm1Dcr/MvwJ - 025201

Albumin is an attractive candidate for half-life extension and conjugates. Albumin-based therapies are rapidly cleared from conventional hFcRn mice because murine albumin out-competes human albumin. This Tg32 albumin-deficient model may be useful for studying the biology and pathobiology of serum albumin as well as evaluating human albumin pharmacokinetics.

The albumin-conjugated drug, Tanzeum, was IV injected into humanzied FcRn mice with (Tg32) and without (Tg32AlbKO) mouse albumin or into mice with no FcRn (FcRn KO). The concentration of circulating Tanzeum in serial blood collections over 30 days was analyzed by ELISA. The drug was rapidly cleared in both Tg32 and FcRn KO mouse models. As expected, the drug had a longer half-life, close to 10 days in the Tg32AlbKO mice.

The Tg276 model is optimal for screening similar antibodies for subtle PK differences

JAX in vivo services use the most widely adopted humanized platform in the industry to compare the half-life of therapeutic antibody candidates and predict their PK in the clinical setting.

These studies use a translationally relevant approach to compare the PK of antibody leads and predict the performance in clinical settings.

Using our humanized transgenic models you will need less NHP for your preclinical studies and still obtain an accurate prediction of the clinical PK